Indication
Ovarian Neoplasm
5 clinical trials
7 products
2 drugs
Clinical trial
Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2026-06-01
Product
NUV-868Product
OlaparibProduct
EnzalutamideClinical trial
Long-Term Follow-Up Study for Subjects Enrolled in the Phase I/II Study of Autologous T Cells Using the Sleeping Beauty System to Express T Cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects With Solid TumorsStatus: Recruiting, Estimated PCD: 2039-04-01
Clinical trial
Phase I/II Study of Autologous T Cells Engineered Using the Sleeping Beauty System to Express T-Cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects With Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2025-12-01
Product
AldesleukinClinical trial
A Randomized Trial of Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced NeuropathyStatus: Not yet recruiting, Estimated PCD: 2027-02-01
Product
Tart Cherry JuiceClinical trial
Administration of T Cells Expressing B7-H3 Specific Chimeric Antigen Receptors (CAR) and Containing the Inducible Caspase 9 Safety Switch in Subjects With Recurrent Platinum Resistant Epithelial Ovarian CancerStatus: Not yet recruiting, Estimated PCD: 2026-03-01
Product
iC9-CAR.B7-H3 T cellsDrug
cyclophosphamideDrug
fludarabine